Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
SEATTLE, WA
/ ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR
TM and ADAPTIR-FLEX
TM platform technologies, today announced that it will present two new posters at the American Association for Cancer Research Virtual Annual Meeting, to be held in two virtual sessions - Saturday, April 10
th to Thursday, April 15
th, 2021 and Monday, May 17
th to Friday, May 21
st, 2021.
Title: APVO603:
A Dual 4-1BB and OX40 bispecific approach utilizing ADAPTIR technology designed to deliver a conditional T cell/NK response against solid tumors
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. .
ADMA Biologics, Inc.February 26, 2021 GMT
Poster Presentation Highlights the Need for a Polyclonal Hyperimmune Globulin Targeting S. Pneumoniae
to Bridge Vaccination and Seroconversion Across Multiple Serotypes
By Using as an Add-On with a Vaccine or Antibiotics, This Therapeutic Strategy has the Potential to Improve S. Pneumoniae
-Related Hospital Clinical Outcomes
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 26, 2021 (GLOBE NEWSWIRE) ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the presentation of a late-breaking poster at the 2021 American Academy of Allergy, Asthma & Immunology Conference (“AAAAI”) Virtu